Intravascular coagulopathy in discordant xenotransplantation
不一致异种移植中的血管内凝血障碍
基本信息
- 批准号:nhmrc : 140500
- 负责人:
- 金额:$ 15.14万
- 依托单位:
- 依托单位国家:澳大利亚
- 项目类别:NHMRC Project Grants
- 财政年份:2001
- 资助国家:澳大利亚
- 起止时间:2001-01-01 至 2003-12-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The successful treatment of many conditions in which the relevant organ has failed completely and irreversibly, is to replace that organ with a new one ie. to perform a transplant. It is well known that there are far fewer organs available for transplantation than the number needed. This means that for those conditions where a supportive treatment is available, eg. the artificial kidney, patients must be maintained by that method, however for other organs such as hearts, lungs and livers, there is no mechanical substitute. If these patients do not receive a transplant, they die. A solution to this problem is to use organs from animals. This is called xenotransplantation. The pig is the most suitable donor, however despite many similarities to humans which make it suitable, there are many differences which are still to be overcome before we can use xenotransplants clinically. These differences are at a very fine molecular level and prevent the normal integration of the organ into the new recipient. The result is that the new organ is rejected within minutes. This process is called hyperacute rejection and by research into its mechanism it was found to be due to just a few differences. We and others have genetically modified pigs so that they have the human genes and this has completely prevented this form of rejection. However,we have found a second barrier which causes a rejection response after a few days. It is now known that a major component of the cause of this second barrier is a few differences in the clotting system. We propose to make further genetic modifications which we think will prevent this rejection. This project proposes to examine various genetic modifications and test their effect in small animal models before going on to make and test pigs into which human genes have been inserted. If we are successful, the possibility of replacing failed human organs with animal organs will be a step closer.
对于许多相关器官完全不可逆转地衰竭的病症,成功的治疗方法是用一个新的器官代替那个器官。做移植手术。众所周知,可供移植的器官远远少于所需的数量。这意味着对于那些支持性治疗可用的情况,例如:对于人工肾脏,患者必须通过这种方法来维持,然而对于其他器官,如心脏、肺和肝脏,还没有机械替代品。如果这些病人不接受移植,他们就会死亡。解决这个问题的办法是使用动物器官。这被称为异种移植。猪是最合适的供体,尽管它与人类有许多相似之处,但在临床应用异种移植之前,仍有许多差异需要克服。这些差异存在于非常细微的分子水平上,阻碍了器官与新受体的正常整合。结果是新器官在几分钟内就被排斥了。这个过程被称为超急性排斥反应,通过对其机制的研究发现,它是由于一些差异。我们和其他人已经对猪进行了基因改造,使它们具有人类基因,这完全防止了这种形式的排斥。然而,我们发现了第二个屏障,它会在几天后引起排斥反应。现在我们知道,造成这第二道屏障的主要原因是凝血系统的一些差异。我们建议进行进一步的基因改造,我们认为这将防止这种排斥。该项目建议在制造和测试植入人类基因的猪之前,先在小动物模型上检查各种基因修饰并测试它们的效果。如果我们取得成功,用动物器官代替衰竭的人体器官的可能性将更近一步。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Prof Anthony D'Apice其他文献
Prof Anthony D'Apice的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Prof Anthony D'Apice', 18)}}的其他基金
Development of recombinant rsolCD39-PSGL as a novel therapeutic with anti-thrombotic and anti-inflammatory effects
重组rsolCD39-PSGL作为具有抗血栓和抗炎作用的新型治疗剂的开发
- 批准号:
nhmrc : 520697 - 财政年份:2008
- 资助金额:
$ 15.14万 - 项目类别:
NHMRC Development Grants
CD39 protects against renal ischaemic-reperfusion injury
CD39 预防肾缺血再灌注损伤
- 批准号:
nhmrc : 447706 - 财政年份:2007
- 资助金额:
$ 15.14万 - 项目类别:
NHMRC Project Grants
A novel CD39-like ecto-NTPDase of Legionella pneumophila
嗜肺军团菌的新型 CD39 样胞外 NTPD 酶
- 批准号:
nhmrc : 436607 - 财政年份:2007
- 资助金额:
$ 15.14万 - 项目类别:
NHMRC Project Grants
Antithrombotic effect of NTPDase1/CD39
NTPDase1/CD39的抗血栓作用
- 批准号:
nhmrc : 344801 - 财政年份:2005
- 资助金额:
$ 15.14万 - 项目类别:
NHMRC Project Grants
Immune responses to the alpha-Gal xenoantigen
对 α-Gal 异种抗原的免疫反应
- 批准号:
nhmrc : 204700 - 财政年份:2002
- 资助金额:
$ 15.14万 - 项目类别:
NHMRC Project Grants
A unique model of inflammatory bowel disease.
炎症性肠病的独特模型。
- 批准号:
nhmrc : 114401 - 财政年份:2000
- 资助金额:
$ 15.14万 - 项目类别:
NHMRC Project Grants
Antibody dependent cell-mediated allograft rejection: a model of xenograft rejection
抗体依赖性细胞介导的同种异体移植排斥:异种移植排斥的模型
- 批准号:
nhmrc : 981140 - 财政年份:1998
- 资助金额:
$ 15.14万 - 项目类别:
NHMRC Project Grants
相似海外基金
Prevention and mitigation of acute traumatic coagulopathy and bleeding
预防和减轻急性创伤性凝血病和出血
- 批准号:
10700402 - 财政年份:2023
- 资助金额:
$ 15.14万 - 项目类别:
Laboratory to Perform Assays of Coagulopathy Biomarkers for the National Cancer Institute’s COVID-19 in Cancer Patients Study (NCCAPS)
为国家癌症研究所的 COVID-19 癌症患者研究 (NCCAPS) 进行凝血病生物标志物检测的实验室
- 批准号:
10795779 - 财政年份:2023
- 资助金额:
$ 15.14万 - 项目类别:
Endothelial Dysfunction and Restoration in Trauma Induced Coagulopathy
创伤引起的凝血病中的内皮功能障碍和恢复
- 批准号:
10734818 - 财政年份:2023
- 资助金额:
$ 15.14万 - 项目类别:
A Near-Patient, Low Blood Volume Platform for Rapid Comprehensive Evaluation of Coagulation in Trauma Patients
用于快速综合评估创伤患者凝血功能的近患者低血容量平台
- 批准号:
10697216 - 财政年份:2023
- 资助金额:
$ 15.14万 - 项目类别:
Early Treatment With H12-(ADP)-liposomes Ameliorates Post-partum Hemorrhage With Coagulopathy Caused by Amniotic Fluid Embolism in Rabbits.
H12-(ADP)-脂质体的早期治疗可改善兔羊水栓塞引起的产后出血和凝血病。
- 批准号:
23K08828 - 财政年份:2023
- 资助金额:
$ 15.14万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Low Density Neutrophils Link Inflammation and Coagulopathy in COVID-19
低密度中性粒细胞与 COVID-19 中的炎症和凝血病有关
- 批准号:
10276657 - 财政年份:2022
- 资助金额:
$ 15.14万 - 项目类别:
Evaluating Individual Cancer-associated Thrombosis Mechanisms to Inform Personalized Thromboprophylaxis in Patients with Metastatic Bone Disease
评估个体癌症相关血栓形成机制,为转移性骨病患者的个性化血栓预防提供信息
- 批准号:
465447 - 财政年份:2022
- 资助金额:
$ 15.14万 - 项目类别:
Operating Grants
2022 Hemostasis Gordon Research Conference and Seminar
2022戈登止血研究会议暨研讨会
- 批准号:
10468359 - 财政年份:2022
- 资助金额:
$ 15.14万 - 项目类别:
Trauma and Shock-Induced Microvascular Dysregulation and Coagulopathy
创伤和休克引起的微血管失调和凝血病
- 批准号:
10360124 - 财政年份:2022
- 资助金额:
$ 15.14万 - 项目类别:
Evaluating Individual Cancer-associated Thrombosis Mechanisms to Inform Personalized Thromboprophylaxis in Patients with Metastatic Bone Disease
评估个体癌症相关血栓形成机制,为转移性骨病患者的个性化血栓预防提供信息
- 批准号:
469094 - 财政年份:2022
- 资助金额:
$ 15.14万 - 项目类别:
Operating Grants